CA-HAI-ROBOTICS/SKECHERS
20.2.2024 12:01:30 CET | Business Wire | Press release
Skechers USA, a leading global footwear and apparel company, turns to Hai Robotics ("Hai"), a leading global provider of Automated Storage and Retrieval Systems (ASRS), as they launch their new distribution center in Minato City, Tokyo, Japan. Using Hai’s automated goods-to-person system, Skechers is maximizing warehouse operational efficiency, fulfillment speed, and order accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220854625/en/
A Hai Robotics Autonomous Case-handling Mobile Robot (ACR), one of 69 that pick and transport containers to fulfill orders within Skechers’ distribution center. (Photo: Business Wire)
Hai’s solution was chosen for its ability to condense storage — minimizing real estate needed — and easily adapt to changing demand, resolve labor shortage issues, and support long-term business growth.
Supported by material handling consulting company MHE Solutions, Inc., Skechers built their new facility to keep up with rapidly growing demand in the Japanese market and to advance operations that had historically relied on manually laborious tasks. Manual picking processes had been the standard to fulfill orders, but managing staff shortages coupled with expanding SKU variety contributed to high operating costs with limited outbound picking efficiency and speed. After evaluating several automation providers, Skechers ultimately determined Hai Robotics’ HaiPick System was the ideal solution for dependable and effective automated order fulfillment.
The HaiPick System is dense, adaptable to changes in consumer demand, and easily expandable as operations grow. It seamlessly integrated with other technologies in the facility to help Skechers quickly respond to customer orders. The system has also extended employee productivity while reducing physical demand on staff, helping to alleviate disruption from labor shortages.
Within Skechers’ facility, the HaiPick System covers 139,705 square feet and is operated by 69 HaiPick Autonomous Case-handling Mobile Robots (ACRs), which are integrated with Manhattan Associates' cloud-native warehouse management system (WMS). ACRs are highly intelligent, tall pieces of equipment that autonomously navigate narrow aisles of an ASRS constructed of almost any industry-standard racking or shelving with a vertical reach extending up to 32 feet. The robots pick containers off the shelving — transporting up to 8 at any given time for maximum order-batching efficiency — and deliver them to human-operated workstations.
Skechers’ HaiPick System contains 8 ergonomic workstations where operators receive clear instructions on a screen of the product and quantity to be picked to fulfill an order. The product is then scanned, and the system confirms order accuracy before the operator can proceed to the following order.
The HaiPick System is a vital part of the operational success in Skechers’ new distribution facility, helping Skechers maintain the high level of service and satisfaction their customers enjoy as they continue to grow.
“All automation projects have their challenges, but the Hai team has been a very good partner in maintaining a positive, can-do attitude and remaining committed to doing the right thing for the customer by delivering on their design,” said Sophie Houtmeyers, Vice President of Distribution Operations at Skechers, and Michael Pitt, MHE Solutions. “The Hai ACR system facilitated creative application to maximize both utilization of the warehouse floor space and hard-to-reach vertical storage space in a challenging Japanese warehousing design caused by strict fire codes. It has additionally provided productivity gains that are key to the growth of Skechers in the Japan market.”
“We are honored to help Skechers elevate the operations in their new facility and be a key part in the facility’s ability to quickly reach their customers,” said Brian Reinhart, Chief Revenue Officer at Hai Robotics U.S.A. “We are grateful for the trust that MHE and Skechers have placed in us and thrilled with the success seen so far. We will continue to work closely with MHE Solutions and Skechers to further support their warehouse automation journey and help them go above and beyond in their operational efficiency goals.”
About Hai Robotics
Hai Robotics is a leading global provider of Automated Storage and Retrieval Systems (ASRS) committed to elevating the world’s access to inventory through intelligent, fast, efficient warehouse automation that is more accessible to all facilities.
Their award-winning equipment drives highly flexible ASRS constructed of standard racking and almost any container. Hai Robotics’ solutions maximize vertical storage up to 32+ feet, reduce storage footprints up to 75%, increase workflow efficiency gains up to 4x, and improve order pick accuracy to 99.9%+.
Founded in 2016, Hai Robotics is trusted in 1,100+ projects across 40+ countries and supported by 8 offices globally. For more information, visit HaiRobotics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220854625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
